Krystal Biotech Stock Cash Per Share
| KRYS Stock | USD 161.76 4.82 3.07% |
Krystal Biotech fundamentals help investors to digest information that contributes to Krystal Biotech's financial success or failures. It also enables traders to predict the movement of Krystal Stock. The fundamental analysis module provides a way to measure Krystal Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Krystal Biotech stock.
Krystal |
Krystal Biotech Company Cash Per Share Analysis
Krystal Biotech's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Krystal Biotech Cash Per Share | 16.58 X |
Most of Krystal Biotech's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Krystal Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Krystal Biotech has a Cash Per Share of 16.58 times. This is 281.15% higher than that of the Biotechnology sector and 282.91% higher than that of the Health Care industry. The cash per share for all United States stocks is notably lower than that of the firm.
Krystal Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Krystal Biotech's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics of similar companies.Krystal Biotech is currently under evaluation in cash per share category among related companies.
Krystal Fundamentals
| Return On Equity | 0.0168 | ||||
| Return On Asset | -0.0883 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 4.03 B | ||||
| Shares Outstanding | 28.56 M | ||||
| Shares Owned By Insiders | 12.77 % | ||||
| Shares Owned By Institutions | 92.37 % | ||||
| Number Of Shares Shorted | 2.45 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 5.90 X | ||||
| Price To Sales | 90.61 X | ||||
| Revenue | 50.7 M | ||||
| EBITDA | (92.22 M) | ||||
| Net Income | 10.93 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 8.09 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 27.58 X | ||||
| Cash Flow From Operations | (88.8 M) | ||||
| Short Ratio | 7.84 X | ||||
| Earnings Per Share | 0.39 X | ||||
| Target Price | 189.0 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 4.62 B | ||||
| Total Asset | 818.36 M | ||||
| Retained Earnings | (269.83 M) | ||||
| Working Capital | 554.82 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
| Net Asset | 818.36 M |
About Krystal Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Krystal Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Krystal Biotech's short interest history, or implied volatility extrapolated from Krystal Biotech options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Krystal Biotech Piotroski F Score and Krystal Biotech Altman Z Score analysis. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Krystal Stock analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.